Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (…

Immunotherapies based on immune checkpoint blockade have shown remarkable clinical
outcomes and durable responses in patients with many tumor types. Nevertheless, these …

Vaccination, being able to prevent millions of cases of infectious diseases around the world
every year, is the most effective medical intervention ever introduced. However, …

Given the long-term ineffectiveness of current therapies and late-stage diagnoses, lung cancer
is a leading cause of malignant diseases. Tumor progression is influenced by cancer cell …

Non-small cell lung cancer (NSCLC) is a leading cause of cancer death. Tumor progression
depends on interactions of cancer cells with the tumor microenvironment. Here, we find …

TRF1 is an essential component of the telomeric protective complex or shelterin. We previously
showed that dysfunctional telomeres in alveolar type II (ATII) cells lead to interstitial lung …

Simple Summary Immunotherapy has been positioned as frontline therapy for advanced non-small
cell lung cancer (NSCLC), alone when PD-L1 tumor expression is high, or combined …

Short/dysfunctional telomeres are at the origin of idiopathic pulmonary fibrosis (IPF) in
patients mutant for telomere maintenance genes. However, it remains unknown whether …

Recent studies highlight the importance of baseline functional immunity for immune
checkpoint blockade therapies. High‐dimensional systemic immune profiling is performed in a …

Cycloplatinated complexes based on 2‐(4‐substituted)benzothiazole ligands of type [Pt(R‐PBT‐κC,N)Cl(L)]
(PBT=2‐phenylbenzothiazole; R=Br (1), Me 2 N (2); L=dimethyl sulfoxide (…